27th Apr 2010 17:16
VERNALIS PLC
ANNUAL INFORMATION UPDATE
As required under Prospectus Rule 5.2, and following publication of the Annual Report on 12th April 2010, the following summarises the information and documents published or made available to the public by the Company between 29th May 2009 and 27th April 2010 inclusive.
This Annual Information Update is also being made available on the Investors section of the Company's website at www.vernalis.com.
The information referred to in this Annual Information Update was correct at the time it was published but some information may now be out of date.
1. Announcements made via a Regulatory Information Service ("RIS")
|
Date |
Description of Contents of Announcement |
|
28/05/09 |
Annual Information Update |
|
29/05/09 |
Director/PDMR Shareholding |
|
01/06/09 |
Director/PDMR Shareholding |
|
02/06/09 |
Holding(s) in Company |
|
02/06/09 |
Vernalis' Partner, SK Chemicals, Secures Approval for Frovatriptan in Korea |
|
03/06/09 |
Interim Management Statement |
|
25/06/09 |
Result of AGM |
|
16/07/09 |
Vernalis Receives Milestone Payment from Novartis in Relation to the Hsp90 Inhibitor Collaboration |
|
21/07/09 |
Vernalis Announces New Oncology Development Candidate in its Checkpoint Kinase 1 (Chk1) Research Programme in Oncology |
|
06/08/09 |
Announcement of Interim Results - Part 1 |
|
06/08/09 |
Announcement of Interim Results - Part 2 |
|
06/08/09 |
Vernalis and GlaxoSmithKline Enter into a Collaboration, Option and License Agreement over a Novel Vernalis Oncology Programme |
|
06/08/09 |
GlaxoSmithKline Announces Notifiable Interest in shares in Vernalis plc |
|
08/08/09 |
Notice of 2009 Half Year Results |
|
11/08/09 |
Holding(s) in Company |
|
11/08/09 |
Holding(s) in Company |
|
12/08/09 |
Holding(s) in Company |
|
20/08/09 |
Admission of Subscription Shares to GlaxoSmithKline in Relation to Collaboration, Option and License Agreement over a Novel Vernalis Oncology Programme |
|
21/08/09 |
Holding(s) in Company |
|
24/08/09 |
Holding(s) in Company |
|
24/08/09 |
Holding(s) in Company |
|
09/09/09 |
Holding(s) in Company |
|
15/09/09 |
Recruitment Completed in V3381 Phase II IN-STEP Study |
|
06/10/09 |
Pilot Study of V3381 in Chronic Cough is Initiated |
|
12/11/09 |
Interim Management Statement |
|
11/12/09 |
Vernalis Earns Milestone Payment from Ipsen in Relation to its 2008 Sale of Apokyn and its US Commercial Operations |
|
14/12/09 |
Vernalis Announces Clinical Update in Relation to its Hsp90 Compounds Partnered with Novartis |
|
11/02/10 |
Placing and Open Offer |
|
11/02/10 |
Publication of Prospectus |
|
01/03/10 |
Placing & Open Offer Result |
|
01/03/10 |
Results of General Meeting |
|
02/03/10 |
Voting Rights and Capital |
|
05/03/10 |
Holding(s) in Company |
|
05/03/10 |
Holding(s) in Company |
|
05/03/10 |
Holding(s) in Company |
|
08/03/10 |
Vernalis Regains European Royalty Rights Receivable from Menarini's Sales of Frovatriptan Following Termination of the Paul Capital Healthcare Agreements |
|
15/03/10 |
Vernalis Receives Milestone Payment from its Partner Novartis in Relation to the Hsp90 Inhibitor Collaboration |
|
24/03/10 |
V3381 IN-STEP Phase IIb Study Results Announced |
|
30/03/10 |
Holding(s) in Company |
|
01/04/10 |
Notice of Results |
|
12/04/10 |
Announcement of Results for the Year Ended 31 December 2009 |
|
16/04/10 |
Director/PDMR Shareholding |
|
16/04/10 |
Director/PDMR Shareholding |
|
27/04/10 |
AGM and Annual Report Notice |
All of the above UK regulatory announcements have been made via a RIS and can be obtained from the London Stock Exchange's website at www.londonstockexchange.com or the Company's website at www.vernalis.com.
2. Documents filed at Companies House
All the documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated.
|
Date |
Document Type |
|
08/06/09 |
Form 88(2) - Return of Allotment of Shares |
|
30/06/09 |
Annual General Meeting Resolutions |
|
12/08/09 |
Form 122 - Notice of Cancellation of Deferred and A Deferred Shares |
|
17/08/09 |
Form 363(a) - Annual Return |
|
26/08/09 |
Form 88(2) - Return of Allotment of Shares |
|
30/09/09 |
Form 288b - Terminating Appointment of Director/Secretary |
|
30/09/09 |
Form 288a - Appointment of Secretary |
|
30/01/10 |
Form TM01 - Terminating Appointment of Director |
|
30/01/10 |
Form TM01 - Terminating Appointment of Director |
|
01/03/10 |
New Articles of Association |
|
01/03/10 |
Form SH02 - Notice of Consolidation, Subdivision, Redemption of Shares or Re-Conversion of Stock into Shares |
|
01/03/10 |
General Meeting Resolutions |
|
02/03/10 |
Form SH01 - Return of Allotment of Shares |
|
02/03/10 |
Form SH03 - Return of Purchase of Own Shares |
|
02/03/10 |
Form SH06 - Notice of Cancellation of Shares |
Copies of the above documents, filed with the Registrar of Companies, can be obtained from the Companies House website at www.companieshouse.gov.uk, or can be obtained from Companies House, Crown Way, Cardiff, CF14 3UZ.
3. Documents published or sent to Shareholders or filed with the UK Listing Authority or submitted to the FSA
All the documents below were sent to shareholders and/or submitted to the FSA/UKLA on or around the dates indicated.
|
Date |
Document |
|
17/08/09 |
Application for Admission of Securities to the Official List |
|
17/08/09 |
Form 1 - Application for Admission of Securities to Trading |
|
20/08/09 |
Confirmation Letter to UKLA Re. Issue of Shares to GSK |
|
08/01/10 |
Form A - Application for the Approval of a Prospectus in Accordance with Part VI of the FSMA 2000 |
|
11/02/10 |
Prospectus (inc Notice of General Meeting), Form of Proxy and Application Form |
|
11/02/10 |
Share Capital Reorganisation Letter to UKLA |
|
23/02/10 |
Share Capital Reorganisation Letter to London Stock Exchange |
|
23/02/10 |
Application for Admission of Securities to the Official List |
|
23/02/10 |
Form 1 - Application for Admission of Securities to Trading |
|
01/03/10 |
General Meeting Resolutions |
|
27/04/10 |
Annual Report, Notice of Annual General Meeting, Form of Proxy and New / Amended Current Articles of Association |
Certain documents submitted to the FSA can be viewed at the Document Viewing Facility situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.
The Notice of Annual General Meeting and Annual, Interim and Preliminary Reports are also available via the Investors section of the Company's website at www.vernalis.com.
4. Further Information
Further information about Vernalis plc can be found on the Company's website at www.vernalis.com.
Enquiries:
|
Vernalis |
+44 (0) 118 989 9360 |
|
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
|
|
|
Brunswick Group |
+44 (0) 20 7404 5959 |
|
Jon Coles Justine McIlroy Will Carnwath
|
|
|
Taylor Rafferty |
+44 (0) 20 7614 2900 |
|
Rob Newman Faisal Kanth
|
|
About Vernalis:
Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eleven candidates in development, eight of which are designated priority programmes. Five of these priority programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Biogen Idec, Chiesi, Endo, GSK, Menarini, Novartis and Servier. For further information about Vernalis, please visit http://www.vernalis.com.
Related Shares:
Vernalis PLC